Critical Insights From Enovis Analyst Ratings: What You Need To Know
In the latest quarter, 4 analysts provided ratings for Enovis (NYSE:ENOV), showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 1 | 1 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 1 | 0 | 0 |
| 2M Ago | 1 | 0 | 0 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $69.75, a high estimate of $82.00, and a low estimate of $53.00. This current average represents a 8.22% decrease from the previous average price target of $76.00.
Investigating Analyst Ratings: An Elaborate Study
An in-depth analysis of recent analyst actions unveils how financial experts perceive Enovis. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Vijay Kumar | Evercore ISI Group | Lowers | Outperform | $62.00 | $70.00 |
| Robbie Marcus | JP Morgan | Announces | Neutral | $53.00 | - |
| Mike Matson | Needham | Maintains | Buy | $82.00 | $82.00 |
| Mike Matson | Needham | Maintains | Buy | $82.00 | - |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Enovis. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Enovis compared to the broader market.
- Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.
For valuable insights into Enovis's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on Enovis analyst ratings.
About Enovis
Enovis Corp is a medical technology company focused on developing clinically differentiated solutions that generate measurable patient outcomes and transform workflows by manufacturing and distributing high-quality medical devices with a broad use for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company conducts its operations through two operating segments: Prevention & Recovery (P&R) and Reconstructive (Recon). It generates the majority of revenue from the Prevention & Recovery segment.
Financial Milestones: Enovis's Journey
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Enovis's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 27.11% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Enovis's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -13.95% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -2.14%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Enovis's ROA stands out, surpassing industry averages. With an impressive ROA of -1.44%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Enovis's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.43.
Analyst Ratings: Simplified
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.